ABVC News and Press, ABVC BioPharma Inc. From 07/06/22

Fremont, CA - ( NewMediaWire ) - July 06, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Zacks Small-Cap Research report dated June 7, 2022 values...

ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said that it had got approval from a Thai ethics committee for its phase 2 clinical study protocol for its medical device Vitargus. The study protocol was approved by the Central Research Ethics Committee of the National Rese...

ABVC Biopharma (NASDAQ:ABVC) is trading 12% higher after it expanded its co-development partnership with Rgene Corporation to guide the latter's three drug products through completion of Phase II clinical studies. Under the partnership, BioKey, ABVC’s subsidiary, wi...

FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has expanded its co-developme...

ABVC Biopharma (NASDAQ:ABVC) on Thursday said it had submitted its phase 2 study plan for its vitreous substitute Vitargus to an Australian regulatory ethics committee. ABVC said that if the mid-stage study gets the approval of the Australian Bellberry Human Research Ethics Committee, it...

FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase...

ABVC Biopharma (NASDAQ:ABVC) said on Friday that two of its contracts had been terminated after the parties were unable to agree to the final terms of the loan between BioKey and NeuCen. The first contract, which was announced on May 3, was a $3M clinical services agreement between ...

Fremont, CA - ( NewMediaWire ) - June 10, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that two contracts entered into in the last 45 days have been term...

Fremont, CA - ( NewMediaWire ) - June 01, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress for the Phase II part 2 clinical study of ...

ABVC BioPharma (NASDAQ:ABVC) on Wednesday said it had entered into an agreement with Taiwan-based medical device company Orion BioTech to identify global licensing partners. As per the deal, ABVC will use its business relationships globally to find licensing partners for Orion products. In re...